ModeratePharmacokinetic enhancer (booster) for antiretroviral therapy×Long-acting selective α1-adrenoceptor antagonist
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises doxazosin in the liver, and CYP2D6 and CYP2C9 contribute to a lesser extent (doxazosin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cobicistat is a strong inhibitor of the enzyme CYP3A, so it raises the levels of drugs that CYP3A metabolises, and their effects and adverse reactions may increase or last longer (cobicistat SmPC, European Medicines Agency, EMA). Cobicistat is taken with atazanavir or darunavir to boost their levels (EMA). According to the US doxazosin label, strong CYP3A inhibitors may increase doxazosin exposure and with it the risk of low blood pressure (doxazosin label, US Food and Drug Administration, FDA). The documents do not say how much cobicistat raises doxazosin levels.
Symptoms
The main risk is low blood pressure when standing up (orthostatic hypotension) with dizziness and weakness, and rarely fainting (doxazosin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Orthostatic hypotension may develop within the first hours after a dose and infrequently later. Fainting is most likely after the first dose or a dose increase (doxazosin label, US Food and Drug Administration, FDA). With cobicistat, higher levels of drugs metabolised by the enzyme CYP3A may increase or prolong their adverse reactions (cobicistat SmPC, European Medicines Agency, EMA).
Management
The Spanish doxazosin summary of product characteristics (SmPC) advises caution when combining doxazosin with strong CYP3A4 inhibitors and gives ritonavir and other protease inhibitors as examples (doxazosin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cobicistat is not on that list, but its own SmPC describes it as a strong CYP3A inhibitor (cobicistat SmPC, European Medicines Agency, EMA). The US doxazosin label says to monitor blood pressure and symptoms of hypotension when doxazosin is used with strong CYP3A inhibitors (doxazosin label, US Food and Drug Administration, FDA). The combination is not contraindicated, as the cobicistat documents contraindicate only alfuzosin among alpha-1 blockers (EMA; cobicistat FDA label). When starting doxazosin, explain how to avoid symptoms of low blood pressure and what to do if they occur (AEMPS). The US label also says to advise the person not to drive or do hazardous tasks for 24 hours after the first dose, after a dose increase and when treatment restarts after a break (FDA). When cobicistat replaces ritonavir as the booster, use caution during the first 2 weeks, especially if the doses of other drugs were adjusted during ritonavir treatment (EMA). Before and during cobicistat treatment, consider possible interactions, review concomitant medicines and monitor for their adverse reactions (cobicistat FDA label). The documents say nothing about lowering the doxazosin dose with cobicistat.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- AEMPS: Ficha técnica: Doxazosina (nº registro 62655), sección 4.5 (2024)– AEMPS, CIMA, nº registro 62655 (Carduran Neo 4 mg comprimidos de liberación modificada, Viatris), ficha técnica 01/2024 (texto revisado 12/2018), secciones 4.4, 4.5 y 5.2
- FDA: CARDURA (doxazosin) prescribing information (2022)– FDA, DailyMed setid eefc47bc-c10f-49bb-8ef7-5999f798ab39 (Roerig, Pfizer), versión 26 (SPL 20.01.2022, publicada 16.07.2026, texto revisado 12/2020), secciones 7 y 12.3